Using direct oral anticoagulants as a case study, the authors examined how delayed adoption of novel treatments could impact patient health outcomes and cost.
Jinghua He, PhD
Advertisement
Articles by Jinghua He, PhD
Advertisement
Latest Updated Articles
Impact of Delayed Adoption of Novel Atrial Fibrillation TreatmentsPublished: December 11th 2024 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
3
Eliminating Cost Sharing Boosted Follow-Up Colonoscopy Rates
4
Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD
5
